302 related articles for article (PubMed ID: 23006751)
21. Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges.
Smith JM; Rastogi R; Teller RS; Srinivasan P; Mesquita PM; Nagaraja U; McNicholl JM; Hendry RM; Dinh CT; Martin A; Herold BC; Kiser PF
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16145-50. PubMed ID: 24043812
[TBL] [Abstract][Full Text] [Related]
22. Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel.
Gao Y; Katz DF
PLoS One; 2013; 8(9):e74404. PubMed ID: 24040241
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques.
Pereira LE; Clark MR; Friend DR; Garber DA; McNicholl JM; Hendry RM; Doncel GF; Smith JM
Antimicrob Agents Chemother; 2014 May; 58(5):2665-74. PubMed ID: 24566178
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy.
Beigi R; Noguchi L; Parsons T; Macio I; Kunjara Na Ayudhya RP; Chen J; Hendrix CW; Mâsse B; Valentine M; Piper J; Watts DH
J Infect Dis; 2011 Nov; 204(10):1527-31. PubMed ID: 21930612
[TBL] [Abstract][Full Text] [Related]
25. Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring.
Thurman AR; Ravel J; Gajer P; Marzinke MA; Ouattara LA; Jacot T; Peet MM; Clark MR; Doncel GF
Front Cell Infect Microbiol; 2022; 12():799501. PubMed ID: 35350436
[TBL] [Abstract][Full Text] [Related]
26. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue.
Louissaint NA; Cao YJ; Skipper PL; Liberman RG; Tannenbaum SR; Nimmagadda S; Anderson JR; Everts S; Bakshi R; Fuchs EJ; Hendrix CW
AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1443-50. PubMed ID: 23600365
[TBL] [Abstract][Full Text] [Related]
27. Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
Kashuba AD; Gengiah TN; Werner L; Yang KH; White NR; Karim QA; Abdool Karim SS
J Acquir Immune Defic Syndr; 2015 Jul; 69(3):264-9. PubMed ID: 26181703
[TBL] [Abstract][Full Text] [Related]
28. Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings.
Moss JA; Baum MM; Malone AM; Kennedy S; Kopin E; Nguyen C; Gilman J; Butkyavichene I; Willis RA; Vincent KL; Motamedi M; Smith TJ
AIDS; 2012 Mar; 26(6):707-10. PubMed ID: 22210639
[TBL] [Abstract][Full Text] [Related]
29. A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.
Yang KH; Hendrix C; Bumpus N; Elliott J; Tanner K; Mauck C; Cranston R; McGowan I; Richardson-Harman N; Anton PA; Kashuba AD
PLoS One; 2014; 9(10):e106196. PubMed ID: 25350119
[TBL] [Abstract][Full Text] [Related]
30. Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya.
Mugo NR; Mudhune V; Heffron R; Thomas KK; McLellan-Lemal E; Njoroge B; Peacock S; O'Connor SM; Nyagol B; Ouma E; Ridzon R; Wiener J; Isoherranen N; Erikson DW; Ouattara LA; Yousefieh N; Jacot TA; Haaland RE; Morrison SA; Haugen HS; Thurman AR; Allen SA; Baeten JM; Samandari T; Doncel GF
Front Reprod Health; 2023; 5():1118030. PubMed ID: 37383290
[TBL] [Abstract][Full Text] [Related]
31. An intravaginal ring for the simultaneous delivery of multiple drugs.
Baum MM; Butkyavichene I; Gilman J; Kennedy S; Kopin E; Malone AM; Nguyen C; Smith TJ; Friend DR; Clark MR; Moss JA
J Pharm Sci; 2012 Aug; 101(8):2833-43. PubMed ID: 22619076
[TBL] [Abstract][Full Text] [Related]
32. Increased Dapivirine tissue accumulation through vaginal film codelivery of dapivirine and Tenofovir.
Akil A; Devlin B; Cost M; Rohan LC
Mol Pharm; 2014 May; 11(5):1533-41. PubMed ID: 24693866
[TBL] [Abstract][Full Text] [Related]
33. Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety.
Nixon B; Jandl T; Teller RS; Taneva E; Wang Y; Nagaraja U; Kiser PF; Herold BC
Antimicrob Agents Chemother; 2014; 58(2):1153-60. PubMed ID: 24323471
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Abdool Karim Q; Abdool Karim SS; Frohlich JA; Grobler AC; Baxter C; Mansoor LE; Kharsany AB; Sibeko S; Mlisana KP; Omar Z; Gengiah TN; Maarschalk S; Arulappan N; Mlotshwa M; Morris L; Taylor D;
Science; 2010 Sep; 329(5996):1168-74. PubMed ID: 20643915
[TBL] [Abstract][Full Text] [Related]
35. Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.
Thurman AR; Brache V; Cochon L; Ouattara LA; Chandra N; Jacot T; Yousefieh N; Clark MR; Peet M; Hanif H; Schwartz JL; Ju S; Marzinke MA; Erikson DW; Parikh U; Herold BC; Fichorova RN; Tolley E; Doncel GF
PLoS One; 2022; 17(10):e0275794. PubMed ID: 36215267
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Gunawardana M; Dawson LN; Olive TJ; Pyles RB; Baum MM
PLoS One; 2018; 13(8):e0201952. PubMed ID: 30133534
[TBL] [Abstract][Full Text] [Related]
37. Vaginal deployment and tenofovir delivery by microbicide gels.
Gao Y; Yuan A; Chuchuen O; Ham A; Yang KH; Katz DF
Drug Deliv Transl Res; 2015 Jun; 5(3):279-94. PubMed ID: 25874971
[TBL] [Abstract][Full Text] [Related]
38. A randomized, comparative safety study of a prefilled plastic and user-filled paper applicator with candidate microbicide tenofovir 1% gel.
Cohen JA; Brache V; Foster J; Cochon L; Callahan M; Schwartz J
Sex Transm Dis; 2013 Jun; 40(6):476-81. PubMed ID: 23677021
[TBL] [Abstract][Full Text] [Related]
39. Genital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral Administration.
Ouattara LA; Thurman AR; Jacot TA; Cottrell M; Sykes C; Blake K; Fang X; Ju S; Vann NC; Schwartz J; Doncel GF
J Acquir Immune Defic Syndr; 2022 Jan; 89(1):87-97. PubMed ID: 34878438
[TBL] [Abstract][Full Text] [Related]
40. Design of tenofovir-UC781 combination microbicide vaginal gels.
Kiser PF; Mahalingam A; Fabian J; Smith E; Damian FR; Peters JJ; Katz DF; Elgendy H; Clark MR; Friend DR
J Pharm Sci; 2012 May; 101(5):1852-64. PubMed ID: 22359356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]